Trippoli Sabrina
Coordinamento HTA, Ente per i Servizi Tecnici Amministrativi della Regione Toscana, Firenze.
Recenti Prog Med. 2017 Sep;108(9):374-378. doi: 10.1701/2745.27989.
The field of medical devices is characterized by a paucity of cost-effectiveness data that support their use. In this context, we have proposed a project based on the calculation of net monetary benefit (NMB) for each product subjected to procurement through tenders. This project consists of two steps: 1) calculation of NMB; 2) calculation of a value-based score to be used in the process of procurement and tendering. The NMB is defined as follows: NMB per patient= (monetary threshold of WTP) x (QALYs per patient) - (treatment cost per patient); WTP= willingness to pay]. Its main advantage is represented by the linear relation between NMB and unit price as opposed to the non-linear relationship that links the ICER to the unit price of the device. For all devices included in the same tender lot, our procedure firstly determines the valus of NMB and converts the NMB into a tender score determined on a 0-to-100 scale. The device with the worst pharmacoeconomic profile is assigned a tender score of 0 while the one with the best pharmacoeconomic profile is assigned a tender score of 100.
医疗设备领域的特点是缺乏支持其使用的成本效益数据。在此背景下,我们提出了一个基于计算通过招标采购的每种产品的净货币效益(NMB)的项目。该项目包括两个步骤:1)计算NMB;2)计算用于采购和招标过程的基于价值的分数。NMB的定义如下:每位患者的NMB =(支付意愿的货币阈值)×(每位患者的质量调整生命年)-(每位患者的治疗成本);WTP =支付意愿]。其主要优点表现为NMB与单价之间的线性关系,这与将增量成本效果比(ICER)与设备单价联系起来的非线性关系形成对比。对于包含在同一招标批次中的所有设备,我们的程序首先确定NMB的值,并将NMB转换为在0到100的范围内确定的招标分数。药物经济学概况最差的设备被赋予0分的招标分数,而药物经济学概况最佳的设备被赋予100分的招标分数。